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CASE REPORT
Mr. W, a 44-year-old male, first presented in 1985 with
microscopic hematuria and proteinuria. Renal biopsy at
that time confirmed IgA nephropathy. His renal function
gradually deteriorated. In August 1997, he reached end-
stage renal disease and continuous ambulatory peritoneal
dialysis (CAPD) was initiated. His clinical course was
uneventful during dialysis and he was never transfused.
He received a living-unrelated kidney transplantation in
March 1999. The donor was his wife, aged 44 and was
of blood group O. Mr. W was of blood group A. The
couple had two children, the youngest being 9-years-
old. There were two A matches, one B and one DR
mismatches (the donor was homozygous for B and DR).
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ABSTRACT
Alloimmune hemolytic anemia has been extensively reported after ABO-mismatch solid organ
transplantation. Alteration of immunosuppressive regimen is generally considered not useful and
may precipitate graft rejection. We present a case of alloimmune hemolytic anemia that coexisted
with acute cellular rejection after living-unrelated kidney transplantation. Reticulocyte count rose
rapidly after azathioprine was stopped and changed to mycophenolate mofetil (MMF). Repeated
transfusion was not required. Enhanced erythropoietic response probably accounts for the prompt
clinical recovery of this condition.
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The operation was smooth and there was immediate urine
output. Blood loss was minimal. Postoperative
hemoglobin was 10.6 g/dL. Triple immunosuppression
with prednisolone, azathioprine, and cyclosporine A was
started. His best serum creatinine was 130 µmol/L on
day 4. He was discharged on day 11 with prednisolone
0.5 mg/kg/day, azathioprine 2 mg/kg/day, cyclosporine
A 8 mg/kg/day, famotidine 40 mg nocte, and nifedipine
SR 20 mg bd. His serum creatinine was 135 µmol/L,
hemoglobin 9.5 g/dL, and whole blood cyclosporine A
level was 350 ng/mL.
Mr. W presented again on day 14 with an episode of
syncope. Physical examination was unremarkable except
clinical pallor and jaundice. His hemoglobin was 4.7 g/dL,
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mean corpuscular volume (MCV) was 98.3 fL,
reticulocyte count was 1.5%, and platelet count was 129
x 109/L. His serum creatinine rose to 178 µmol/L. Serum
bilirubin was 98 µmol/L, and haptoglobin was 0.06 g/L
(normal 0.33 g/L - 1.71 g/L). Liver enzymes were normal.
Peripheral blood smear showed macrocytosis and
polychromasia without schistocyte. Serologic test for
parvovirus infection was negative.
The patient was transfused with four units of group A
pack cells. Direct Coombs test was positive (previous
Coombs test before kidney transplant was negative). Cold
agglutinin test was also negative. Glucose 6-phosphate
dehydrogenase (G6PD) status was normal. Trough whole
blood cyclosporine A level was 153 ng/mL. Kidney
biopsy showed mild acute cellular rejection with
interstitial mononuclear cell infiltration and occasional
tubulitis. There were no intraglomerular thrombi, which
suggests of hemolytic uremic syndrome. The diagnosis
of alloimmune hemolytic anemia secondary to passenger
lymphocyte was made.
T h e  p a t i e n t  w a s  g i v e n  i n t r a v e n o u s  p u l s e
methylprednisolone 500 mg for 3 days for graft rejection.
The dosage of cyclosporine A was increased to keep the
trough whole blood level of 250 ng/mL to 300 ng/mL.
However, his hemoglobin remained around 7 g/dL.
Reticulocyte count was less than 2%. Azathioprine was
stopped 4 days later because of possible impaired
erythropoietic response. Mycophenolate mofetil (MMF)
500 mg tds was started to maintain adequate immuno-
suppression.
The patient's reticulocyte count rose promptly 5 days
afterward, and reached a peak of 20% 2 weeks later (Fig.
1). Hemoglobin level rose subsequently and became
stable around 14 g/dL 3 weeks later. No further blood
transfusion was required. His serum creatinine also
decreased to around 160 µmol/L. MMF was continued
for 4 weeks and then changed back to azathioprine 1.5
mg/kg/day. The patient is now completely well 6 months
after kidney transplantation. His serum creatinine is 160
µmol/L and hemoglobin is 15 g/dL.
DISCUSSION
Alloimmune hemolytic anemia after solid organ
transplant is also known as "passenger lymphocyte
syndrome". It was firstly reported in 1964 by Marchioro
et al in splenic allograft recipient (1). In fact,
alloantibodies toward ABO antigens and clinically
relevant hemolysis can be demonstrated in 17% and 9%,
of ABO-mismatch kidney transplant recipients,
respectively (2,3). The incidence is even higher in liver
and heart-lung transplants (2,4), probably because more
passenger lymphocytes are involved.
Although passenger lymphocyte syndrome is generally
self-limiting, patients may develop major complications
such as renal failure during the acute phase of illness
(5). Unlike autoimmune hemolytic anemia, immuno-
suppressive therapy such as cyclophosphamide is usually
of little benefit (6). In fact, alteration of immuno-
suppressive regimen may be related to acute graft
rejection in some cases and is generally not recommended
(2).
In our patient, immuno-suppressive therapy was altered
for a different reason. Although there was no massive
hemolysis after transfusion, reticulocyte count and
Figure 1.  Serial trends of hemoglobin and reticulocyte count of our patient. (Note:
Horizontal axis is not in scale.)
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hemoglobin level remained low. Suppression of
erythropoiesis by azathioprine was considered a distinct
possibility and the drug was therefore stopped. We used
MMF as a substitute to maintain immuno-suppression
because of concurrent graft rejection. MMF specifically
blocks de novo purine synthesis by inhibiting inosine
monophosphate dehydrogenase and has minimal effect
on erythroid lineage proliferation (7). This alteration was
proved successful and reticulocyte count rose after 4 days
(Fig. 1).
Alloimmune hemolysis is usually self-limiting (8). This
is due to gradual depletion of passenger lymphocytes,
which are deprived of survival  signals from
corresponding T-helper cells and follicular dendritic cells
(9). Prompt clinical improvement in our patient might
merely be the natural course of his illness. However, the
close timing between termination of azathioprine and the
recovery of reticulocyte count suggests a causal
relationship. Furthermore, hematologic improvement in
our patient began at 3 weeks postoperatively, which was
much earlier than the median of 5 weeks (range 3 to 23
weeks) as reported in untreated cases (8).
Other therapeutic modalities had been considered for our
patient. Transfusion of donor blood group may avoid
acute hemolysis in severe cases (2), and plasmapheresis
may be beneficial in life-threatening cases (10). Although
we used group A pack cell (i.e. that of recipient's blood
group) for our patient, hemoglobin level was sustained
because of the satisfactory bone marrow response.
It should be noted that the evidence of hemolytic anemia
by ABO mismatch was circumstantial. There was no
definite objective evidence of alloimmune hemolytic
anemia in our case. The diagnosis of alloimmune
hemolysis was based on exclusion. Hemolytic uremic
syndrome was ruled out by a positive Coombs test and
renal biopsy. There was no medication or concurrent
infection (e.g. mycoplasma) which could account for the
hemolysis. Although autoimmune hemolysis despite
immuno-suppression is theoretically possible, this is
exceedingly rare and has only been suspected in liver
transplant recipients (11).
In addition to immune hemolysis, our patient also had
mild thrombocytopenia. Thrombocytopenia is present in
4% cases of alloimmune hemolytic anemia after ABO-
mismatch solid organ transplant (2). Immune mechanism
is generally assumed. The platelet count of our patient
became normal with hemoglobin level at the same time.
In summary, we reported a case of alloimmune hemolytic
anemia after ABO-mismatch kidney transplantation that
showed prompt improvement after azathioprine was
stopped and changed to MMF. Enhanced erythropoietic
response probably accelerated the recovery.
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